Immunoglobulin D enhances the release of tumour necrosis factor-a, and interleukin-1b as well as interleukin-1 receptor antagonist from human mononuclear cells by Drenth, J.P.H. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Immunology 1996 88 355-362
Immunoglobulin D enhances the release of tumour necrosis factor-a, 
and interleukin-1/? as well as interleukin-1 receptor antagonist from 
human mononuclear cells
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SUM M ARY
Immunoglobulin D (IgD) is normally present in only low concentrations in serum. In the hyper- 
IgD and periodic fever syndrome (HIDS), however, serum levels exceed 140 mg/1. This syndrome is 
further characterized by recurrent inflammatory febrile attacks together with an acute phase 
response and appearance of cytokines in the circulation. The role of IgD in the pathogenesis of 
HIDS and its relation to the increased cytokine concentrations is unclear, Therefore, we tested 
whether IgD, IgG and apacid glycoprotein (AGP) isolated from human serum influence the 
synthesis of interleukin-1/? (IL-l/f), tumour necrosis factor-a (TNF-a), and IL-lra, as measured by 
specific radioimmunoassays, in human peripheral blood mononuclear cells (PBMC). Incubation of 
PBMC with IgD and AGP for 24hr led to increased release of IL-1/?, TNF-a, and IL-lra. The 
magnitude of stimulation of IgD exceeded that of AGP; the effect by IgD was dose-dependent 
and showed a 30-fold (TNF-a) to almost 150-fold (IL-l/f) increase at the highest concentration 
(50 mg/1), while AGP (750 jug/ml) only increased the cytokine secretion fourfold (TNF-a) to almost 
30-fold (IL-1/?). The effect of IgD on IL-lra was less dramatic but a fivefold increase was observed 
at 50 mg/1 compared with a 2-5-fold increase with AGP, IgD potentiated the effect of 
lipopolysaccharide (LPS) on secretion of both IL-1/? and TNF-a, although the effect was most 
apparent for TNF-a. Apart from inducing IL-lra synthesis, IgG did not influence cytokine release 
in human PBMC. These data indicate that IgD is a potent inducer of TNF-a, IL-1 /? and IL-lra and 
thus may contribute to the pathogenesis of HIDS.
INTRO DUCTIO N
Immunoglobulin D (IgD) was first discovered by Rowe & 
Fahey in 19651 and it is the major antigen receptor iso type 
coexpressed with IgM on the surface of human peripheral B 
cells.2 Its biological function has not been fully elucidated, but 
IgD may be involved in the early antibody response by 
augmenting antibody secretion.3 In serum, IgD is present 
only in minor quantities and it constitutes only some 0-2% of 
all immunoglobulins.4 In normal individuals concentrations 
vary from undetectable to 140 mg/1. Elevated serum IgD may 
be found in several clinical conditions such as IgD myeloma, 
Hodgkin’s disease, sarcoidosis and tuberculosis, aspergillosis, 
ataxia-telangiectasia, acquired immune deficiency syndrome 
and the hyperimmunoglobulinemia D and periodic fever 
(HIDS) syndrome.5 The latter clinical entity is characterized 
by recurrent febrile attacks with abdominal complaints,
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arthralgias/arthritis, skin lesions and an elevated serum IgD 
concentration beyond 140mg/L The serum concentration of 
IgD remains elevated throughout life and does not change with 
disease activity. The attacks are accompanied by an acute phase 
response with high circulating concentrations of a j -acid 
glycoprotein (AGP), C-reactive protein (CRP), soluble type II 
phospholipase A2 and serum amyloid A.6,7 Inflammatory 
cytokines such as interleukin-1 /? (IL-1/?), IL-6 and tumour 
necrosis factor-a (TNF-a) are thought to play a central role in 
multiple effector functions and cellular interactions in inflam­
mation and immune response.8 Uncontrolled secretion leading 
to high levels of inflammatory cytokines may lead to an intense 
inflammatory response as noted in the HIDS. Indeed, elevated 
circulating concentrations of the inflammatory mediators 
TNF-a, IL-1 receptor antagonist (IL-lra), IL-6, interferon-^, 
and soluble receptors for TNF-a (sTNFr) have been detected 
during the febrile episodes.6,9
Upon stimulation with bacterial lipopolysaccharide (LPS, 
endotoxin), monocytes/macrophages are able to produce a 
wide array of cytokines such as IL-1/?, IL-6 and TNF-a.10 
During attacks of HIDS, incubation of whole blood with LPS 
for 24 hr, resulted in an augmented ex vivo secretion of TNF-a,
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IL-1 ji and IL~lra in the supernatants compared with convales­
cence.6 Taken together, these data suggest that inflammatory 
cytokines such as IL-l/j, IL-6 and TNF-a could play a 
pathogenic role in the febrile attacks of the hyper-IgD 
syndrome. Furthermore, it can be speculated that soluble 
compounds present during an attack are responsible for this 
up-regulated cytokine secretion. For example, the acute phase 
protein CRP is able to potentiate the secretion of IL-1/?, IL-lra 
and TNF-a by isolated human monocytes.11 On the other hand, 
the effect of IgD on cytokine secretion is not known. These 
observations prompted us to investigate the capacity of serum 




Serum for IgD isolation was obtained from a patient with the 
hyper-IgD syndrome (patient represents no. 1 in a recent review).5 
During the 13-year follow-up (1981—94) she had IgD concen­
trations varying from 2269 mg/1 to 7484 mg/1. Plasma was 
stored at —20° after the addition of e-aminocaproic acid (final 
concentration 0'5%) to prevent ‘spontaneous’ degradation of 
IgD.12 Sampling of experimental plasma was performed during 
remission, defined as the absence of symptoms for at least 
2 weeks. The patient did not use any medication at the time of 
the study.
Enzyme-linked immunosorbent assay for IgD 
Determination of IgD was performed using a specific enzyme- 
linked immunosorbent assay (ELISA).. Microtitre plates 
(Nunc, Roskilde, Denmark) were directly coated for the 
titration of human IgD with 1:5000 dilution of rabbit anti­
human IgD in 200 p\ bicarbonate buffer, pH 9*5 (Dako, 
Copenhagen, Denmark). As there was no non-specific binding 
detectable in our assay, we did not block the plates with 
albumin. After overnight incubation at 4°, plates were washed 
with phosphate-buffered saline (PBS) containing 0*01% Tween 
20, and samples were added to the wells. Plates were incubated 
again overnight at 4°. A standard human serum (Behring, 
Marburg, Germany), calibrated against the British Research 
Standard No 67/37, was used as a reference.13 The plates 
were washed and 100 (A mouse monoclonal anti-human IgD, 
diluted 1:200 in PBS, was added and incubated for 90min 
at 37°. After a washing step, 100 ¡A horseradish peroxidase 
rabbit anti-mouse anti-IgD (diluted 1:4000 in PBS) (Dako, 
Copenhagen, Denmark) was added and incubated at 37° for 
90min.
After a washing step, IgD was measured by incubation with 
100 fA ortho-phenylenediamine (Sigma, St Louis, MO). The 
reaction was stopped by 4 m  H2SO4 and absorbance was read at 
492 nm using a Titertek Multiskan ELISA reader (Eflab, Oy, 
Helsinki, Finland). The lower limit of detection was 1-4 mg/1.
Preparation and purification of IgD
IgD was prepared from hyper-IgD sera by chromatography on 
diethylaminoethyl (DEAE)-cellulose and CM-C50 columns 
followed by gel filtration on Sephacryl S-300. All steps were 
performed at 4°. Serum was precipitated with polyethylene- 
glycol (PEG) 6000 (final concentration 7%). The precipitate 
was then dissolved in 0*01 m  trishydroxymethylaminomethane
(Tris), 2 m M  ethylenediamine-tetraacetic acid (EDTA), lmivi 
phenylmethylsulphonyl fluoride (PMSF), and finally 0*5 U/ml 
aprotinin, pH 7*8 to prevent proteolysis. The solution was 
applied to a column of DEAE-cellulose (l-5cmx60cm) 
equilibrated in the same buffer. The column was eluted with a 
linear gradient (0 01—0-05 m ) of the Tris buffer. IgD-containing 
fractions were pooled, dialysed against 0*01 m  sodium acetate, 
2 m M  EDTA, 1 h i m  PMSF and 0*5 U/ml aprotinin, pH 6*0 and 
applied to a CM-C50 column (2-5 cm x 15 cm) equilibrated in 
the same buffer. The IgD-positive fractions were again pooled 
and finally applied to a Sephacryl S-300 column (2*5 cm x 
90 cm) equilibrated with a buffer containing veronal buffered 
NaCl, 2 m M  EDTA, 0*15 M NaCl, 1 m M  PMSF and aprotinine, 
pH 7*4, The purity was checked by sodium dodecylsulphate 
(SDS) polyacrylamide gel electrophoresis. The final IgD 
product contained 150 mg/1 IgD as measured by the described 
ELISA and no detectable IgG, IgA or IgM as detected by 
immunoturbidimetric assay (Cobas Fara, Roche Diagnostics, 
Basle, Switzerland). The IgD preparation was dissolved in PBS 
and stored at —70° until use.
The purified IgD preparation was tested for endotoxin 
using the limulus amoebocyte lysate assay (Sigma) and was 
shown to contain less than 6pg/ml endotoxin.
SDS-PAGE and detection o f proteins on membranes 
The purity was checked by SDS-polyacrylamide gel electro­
phoresis (PAGE) following the method of Laemmli.14 Briefly, 
the IgD product was subjected to SDS-PAGE and proteins 
were stained with silver nitrate using a PhastSystem develop­
ment unit (Pharmacia, Uppsala, Sweden). The silver staining is 
able to detect 0*3ng/jiil protein.15 Proteins were blotted on 
nitrocellulose and the blots were incubated with a polyclonal 
anti-IgD antibody (DAKO A093, Dako, Copenhagen, Den­
mark). After a washing step a specific secondary biotinylated 
antibody was added. Bands were visualized with a streptavidin 
complex and photographed.
Preparation of IgG
Purified human serum IgG preparation (Globuman Berna) was 
kindly provided by Primmed BV, the Netherlands. The 
preparation contained more than 95% IgG and no IgA and 
IgM as examined by an automatic immunoturbidimetric assay 
(Cobas Fara, Roche Diagnostics, Basle, Switzerland) and no 
IgD as assessed with ELISA. The IgG preparation was 
dissolved in PBS and stored at —70° until use.
Preparation and purification o f AGP
AGP obtained from Cohn fraction V of pooled human serum 
was a gift of Drs E. Havenaar and W. van Dijk, Free University 
of Amsterdam, the Netherlands. Purification was performed 
following the method of Hao and Wickerhauser using two 
purification steps with absorption on DEAE-Sephadex and 
chromatography on a CM cellulose column.16
The purity was checked by SDS-PAGE and by crossed 
immunoelectrophoresis using rabbit anti-human serum and 
rabbit anti-human AGP antisera (Dako, Copenhagen, Den­
mark) The final preparation was dissolved in PBS and stored at 
— 70° until use.
Isolation of peripheral blood mononuclear cells (PBMC) 
Peripheral blood from healthy, medication-free donors (25-45
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years of age) was drawn into sterile 10-ml tubes containing 
02 mg EDTA. PBMC were isolated by buoyant density 
gradient centrifugation on Percoll.17 The cells from the 
interphase were aspirated and washed twice in sterile saline. 
After the last washing, the cells were resuspended at a 
concentration of 5 x 106/ml in RPMI-1640 medium (Dutch 
modification, Flow Labs, Irvine, UK) supplemented with 2 ih m  
L-glutamine, 1 mM pyruvate and 500 fig/ml gentamicin (Essex, 
Amstelveen, the Netherlands). Medium was subjected to ultra­
filtration to remove endotoxin and other cytokine-inducing 
material.18 Depending on the experiments, either heat- 
inactivated (30min at 56°) or untreated pooled human sera 
(5%) was added after filtration (complete medium). PBMC 
were resuspended at a concentration of 5 x 106/ml in round 
bottom 96-well plastic tissue culture plates (Greiner GMBH, 
Frickenhausen, Germany) and incubated at 37° in a humidified 
atmosphere containing 5% C 02 for 24 hr. PBMC cultures set 
up in the presence of complete medium served as controls. 
After incubation for 24 hr, the culture plates were centrifuged 
at 4000# for lOmin to remove cellular material. Then, the 
cell supernatants were aspirated and cytokine content was 
determined.
Isolation of monocytes by adherence
PBMC were suspended in complete medium at a concentration 
of 5 x i06/ml and allowed to adhere on 96-well plastic tissue 
culture plates (Greiner GMBH) for 1 hr at 37° in a humidified 
atmosphere containing 5% CO2. Non-adherent cells were 
removed by gentle aspiration and were incubated in adjacent 
wells.
Cell stimulation
All experimental preparations were dissolved in complete 
medium before use. PBMC were incubated with various 
concentrations with or without the presence of purified LPS, 
final concentration 100ng/ml (lipopolysaccharide prepared 
from Escherichia coli serotype 055:B5; Sigma).
Source of antiserum
Polyclonal antibodies for IL-1 /? were kindly provided by Sclavo 
(Siena, Italy). Antibodies for TNF-a were a gift of Dr C. A. 
Dinarello (New England Medical Center, Boston, MA) and 
were obtained by immunizing New Zealand White rabbits with 
recombinant human TNF.19 A polyclonal anti-IL-lra anti- 
serum was raised in New Zealand White rabbits immunized 
with recombinant IL-lra kindly provided by Synergen 
(Boulder, CO).20
Radioimmunoassay for cytokines
IL-1/?, TNF-a and IL-lra in plasma were measured in duplicate 
by non-equilibrium radioimmunoassay (RIA) and 100 ¡A of 
rabbit polyclonal antibodies raised against recombinant 
cytokines as described elsewhere [final dilution IL-1/? 
(1:210000), TNF-a (1:150000) and IL-lra (1:60000) which 
gives a binding with the tracer of approximately 25%]. The 
antibodies were dissolved in RIA buffer containing 1 3 m M  
Na2EDTA, 0*02% sodium azide, 0*25% bovine serum albumin 
(Behring, Marburg, Germany), 0*1% Triton-X-100, 3 m M  
Na2HP0 4, and 250 000 kallikrein-inactivating units apoproti- 
nine (Bayer, Leverkusen, Germany) pH 7*4 were added to 
sample ^ and standard.21 All reagents were prepared with this
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buffer. For circulating cytokine measurement 100 //I and for 
measurement of ex vivo cytokine production 25 ¡A (TNF-a) and 
10 (i\ (IL-1/? and IL-lra) of sample and standard were added. 
The mixture was incubated for 1 day at room temperature. 
Subsequently, tracer (approximately 7000 d.p.m./100jA) was 
added, and incubation was continued for another 2 days. To 
separate bound and free tracer from the free fraction, 100 /d of 
a separation agent (10% (vol/vol) sheep anti-rabbit immuno­
globulin G and 0*01% [(wt/vol) rabbit immunoglobulin G 
(Sigma)] was added to each tube and incubated for 30 min at 
room temperature. The antibody complex was completely 
precipitated by the addition of 1 ml 7*5% PEG-6000 (Merck, 
Darmstadt, Germany). For IL-1 ƒ?, TNF-a and IL-lra the range 
of the standard curve was 20pg/ml to 3000pg/ml. The 
sensitivity of the assay with 100/d sample was 60pg/ml (IL- 
lra), 40pg/ml (IL-1/?) and 20pg/ml (TNF-a). There was no 
cross-reactivity between IL-lra and IL-1/? (< 0*001%), TNF-a 
and IL-1/? (<0*01%) and IL-lra and TNF-a (<0*01%). To 
minimize analytical errors, all samples were analysed in the 
same run, in duplicate.
Statistical analysis
All results are shown as the mean ± standard error of the mean 
(SEM). Cytokine concentrations were compared with the non- 
parametric Friedman two-way analysis of variance ( a n o v a ) and 
the unpaired non-parametric Mann-Whitney U test, where 
appropriate. A P value of <0-05 was considered to be the 
lowest level of significance.
RESULTS 
SDS-PAGE analysis of IgD
IgD product was resolved by SDS-PAGE analysis on a 10% 
polyacrylamide gel to observe its integrity and purity. Silver 
nitrate staining showed a band of 185000 MW indicating that 
the purified protein had not undergone aggregation or break­
down during isolation. Immunoblotting with polyclonal anti- 
IgD antibodies indicated that the isolated protein indeed 
consisted of IgD (Fig. 1).
Induction of IL-1/?, TNF-a and IL-lra synthesis in human 
PBMC and adherent monocytes by IgD and IgG
The induction of IL-1 /?, TNF-a and IL-lra by IgD after a 24-hr 
incubation period is shown in Fig. 2. IgD was able to stimulate 
PBMC to a significant increase of the secretion of IL-1/?, 
TNF-a (P < 0*0001), and IL-lra (P < 0*005). Compared to 
results from control medium, a concentration as low as 
0*05mg/1 IgD induced more IL-1/? (1*01 ± 0*86ng/ml versus 
0*16 ± 0*03 ng/ml), IL-lra (10*3 ± 1*91 ng/ml versus 2*4 ± 
0*09ng/ml), and TNF-a (1*09 ± 0*33 ng/ml versus 0*25 ± 
0*08 ng/ml). Induction of IL-1/? and TNF-a by IgD was dose- 
dependent and continued to increase with the maximum 
concentration used (50 mg/1), while the stimulation of IL-lra 
release did not increase appreciably with concentrations above 
0*05 mg/1. The amount of IL-1/? produced by PBMC at a 
concentration of 50 mg/1 was nearly 150-fold the amount in 
control samples, while TNF-a secretion increased almost 
30-fold. IgD at a concentration of 50 mg/1 induced maximal 
IL-lra secretion (13*1 ± 1*94ng/ml). Incubation of IgD with









::•=■!•••• ' f f l .
Figure 1. Silver nitrate-stained SD S-PA G E of isolated human IgD 
(lane 2) showing a band of MW 1S5000 indicating that the purified 
protein had not undergone aggregation or breakdown during isolation. 
There was minor albumin contamination, The sample was then 
immunoprecipitated with polyclonal anti-IgD antibodies, separated 
by SD S-PA G E on a 10% acrylamide gradient gel and then visualized 
by autoradiography (lane 1) The two lanes on the right carry the 
markers with molecular weights as indicated in the left and right margin 
(MW x 10“ 3).
LPS (100ng/ml) enhanced IL-1/? and TNF-a release by PBMC 
( P  < 0*05). Addition of IgD to LPS did not influence IL-lra 
secretion from PBMC.
In order to delineate which cells were most responsive to 
IgD stimulation, monocytes were separated by adherence and 
cytokine secretion after 24 hr IgD stimulation was estimated. 
As shown in Table 1 monocytes secreted more IL-1/? and 
TNF-a compared with non-adherent cells. This emphasizes the 
critical role of monocytes with regard to cytokine release in 
response to IgD stimulation in our system with a mixed cell 
population.
The time-course of IL-1/?, TNF-a and IL-lra production 
from PBMC in response to IgD (5 mg/1) was studied next and
Table 1. Comparison of effect of a 24-hr incubation of IgD on TNF-a 
and IL-1/? release (ng/ml) from PBMC, adherent monocytes and non-
adherent cells
IgD (mg/l)
0 0-05 0*5 5 50
TNF-a release
PBMC 0*08 0'2 7*4 10 10
Adherent monocytes 0*13 0*505 4*1 6*95 10
Non-adherent cells 0*08 0*125 2*25 3-95 1*7
IL-}p release
PBMC 0*085 0*5 33 10 20
Adherent monocytes 0*075 0*4 2*05 16*5 25*5
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Figure 2, IgD induces IL-1/? (a), TNF-a (b) and IL-lra (c) synthesis by 
PBMC. PBMC were stimulated by 0-50 mg/I human IgD in the absence 
(open blocks) or presence (hatched blocks) of Escherichia coli LPS 
(100 ng/ml). After 24 hr, the cultures were harvested and assayed for 
IL-1/?, TNF-a and IL-lra. Data are expressed as means ± standard 
errors and are derived from seven to 11 different experiments; 
P < 0*001 (IL-1/? and TNF-a), and P < 0-005 (IL-lra) when comparing
PBMC treated with different concentrations of IgD in the presence or
\
absence of LPS compared with untreated PBMC.
compared with that of LPS-stimulated PBMC (Fig. 3). 
Measurable amounts of IL-1/? (0*28 ±  0*09 ng/ml), TNF-a 
(0*82 ± 0*04ng/ml) and IL-lra (0*76 ±  0*1 ng/ml) were detec­
ted after 2-hr incubation with IgD. After 2-hr and 4-hr 
incubation PBMC released more IL-1/? but not TNF-a or 
IL-lra with IgD than with LPS. Peak concentrations of TNF-a 
(4*38 ± 1*3 ng/ml) were already attained after 6-hr incubation 
with IgD and a non-significant decrease was observed after 
prolonged incubation (at 24 hr, 2*73 ± 0*48 ng/ml). After 12-hr 
incubation, both IL-1/? (12*4 ± 1*56ng/ml) and IL-lra 
(7*8 ± 2*1 ng/ml) reached maximal concentrations with cyto­
kine release from -PBMC slightly diminishing after prolonged 
incubation.
To investigate the possibility that the effects observed with 
IgD were caused by endotoxin contamination, PBMC were 
incubated with polymyxin B (25 ¿ig/ml). As shown in Table 2, 
polymyxin B did not influence the effect of IgD but gave a 
reduction of the LPS-induced IL-1 p and TNF-a release, The 
incubation with polymyxin B did not influence the IL-lra 
release by IgD or LPS. As an additional control for endotoxin 
contamination, the IgD preparation was heated in a poly­
propylene tube incubated in a waterbath at 100° for 1 hr. 
Exposure of PBMC to the IgD preparation resulted in
1996 Blackwell Science Ltd, Immunology, 88, 355-362
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Figure 3. Effect of time of addition of human IgD or LPS on IL-1/Ï (a), 
TNF-a (b) and IL-lra (c). PBMC were treated with human IgD (open 
blocks) (5 mg/1) or LPS (cross-hatched blocks) (100 ng/ml) At 2,4, 6, 8, 
12 or 24 hr cultures were harvested and cytokines were measured in the 
supernatants, Data are depicted as the mean ± standard error of five 
different donors; P < 0-005 when comparing PBMC treated with IgD 
compared with untreated PBMC.
substantial reduction of IL-1/? (360pg/ml) and TNF-a (100 pg/ 
ml) release, to values comparable to those from cultures 
incubated without stimuli. This excludes the possibility that the 
stimulation by the IgD preparation was caused by endotoxin, 
which is relatively heat stable.
As shown in Fig/ 4, human IgG was a potent stimulator for 
IL-lra production (P < 0*005). As little as 0-05mg/1 IgG was 
able to release appreciable IL-lra concentrations compared 
with baseline (8T ± 1*3 ng/ml versus 2*4 ± 0*17 ng/ml). The 
maximal effect was observed at concentrations of 0*5 mg/1, but 
the effect was smaller compared with IgD. In contrast, the 























0 0-05 0*5 2-5
IgG (mg/l)
50
Figure 4. Effect of increasing concentrations of human IgG on the 
induction of IL-1/? (a), TNF-a (b) and IL-lra (c) synthesis by PBMC. 
PBMC were stimulated by 0-50 mg/l human IgG in the absence (open 
blocks) or presence (hatched blocks) of Escherichia coli LPS (100ng/ 
ml). After 24hr, the cultures were harvested and assayed for IL-1 /?, 
TNF-a and IL-lra. Data are expressed as means ± standard errors and 
are derived from four different experiments; P < 0-005 (IL-lra) when 
comparing PBMC treated with different concentrations of IgD in the 
absence of LPS compared with untreated PBMC,
TNF-a release in the same cultures. Also, IgG did not influence 
the LPS-induced cytokine production by PBMC.
Effect of complemcnt-containing serum
Because C5a induces TNF-a and IL-1/? messenger RNA from 
PBMC in vitro,22 we investigated the contribution of comple­
ment to the IgD-induced cytokine release. As the complete 
medium used in all previous experiments contained serum 
deprived of complement by heat inactivation (30 min at 57°),
Table 2. PBMC were incubated for 24 hr. Data represent mean ± SEM from four experiments. 
Polymyxin B was used at a concentration of 25 fig/ml.
Stimulus Inhibitor IL-1/? (ng/ml) TNF-a (ng/ml) IL-lra (ng/ml)
IgD (5 mg/l) --- 26 ±3-1 4-7 ± 0*3 9-5 ± 1*7
IgD (5 mg/l) Polymyxin B 21-5 ±4-5 5*8 ± i 9*8 ± 2-7
LPS (100 ng/ml) --- 31-1 ± 13 6 ±  L 6 8*35 ± 1*6
LPS (100 ng/ml) Polymyxin B 11-4 ±6*11 1-7 ±0*57* 8*32 ± 2*1
*P < 0-05 from LPS alone.
© 1996 Blackwell Science Ltd, Immunology, 88, 355-362
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Figure 5. Effect of increasing concentrations of human AGP on the 
induction ofIL-1// (a), TNF-a (b) and IL-lra (c) synthesis by PBMC. 
PBMC were stimulated by 0-1000/jg/ml human AGP in the absence 
(open circles ) or presence (solid circles) of Escherichia coli LPS (100 ng/ 
ml). After 24 hr, the cultures were harvested and assayed for IL-1 f t  
TNF-a and IL-lra. Data are expressed as means ± standard errors and 
are derived from five different experiments; P < 0*005 when comparing 
PBMC treated with different concentrations of AGP in the presence or 
absence of LPS compared with untreated PBMC.
non-treated complement-containing serum was added to com­
plete medium. This did not change the IgD-induced IL-1 ft 
TNF-a and IL-lra release from PBMC (data not shown.)
Induction of IL-1 ft TNF-a and IL-lra synthesis in human 
PBMC by AGP
AGP was also tested for its potential to elicit IL-1 ft TNF-a 
and IL-lra release from PBMC (Fig. 5). PBMC from five 
different donors incubated with AGP produced about two- to 
fourfold more cytokines compared with unstimulated controls 
(P < 0'05), The maximal effect of AGP on production of the 
various cytokines was observed with 750/zg/ml and higher 
concentrations did not yield different results. PBMC were also 
incubated with 100 /¿g/ml LPS and increasing concentrations of 
AGP. The LPS-stimulated synthesis of IL-lra was significantly 
enhanced in the presence of AGP, whereas no such effect was 
detectable for TNF-a and IL-l/? (P < 0-05).
DISCUSSION
This study demonstrates for the first time that human serum 
IgD enhances cytokine secretion from PBMC in vitro. The
effect was dose-dependent and showed an almost 150-fold 
(IL-1/?) and 30-fold (TNF-a) increase at the highest concentra­
tion of IgD used (50mg/1). The effect on IL-lra was less 
dramatic but a fivefold increase was observed at 50 mg/1. 
Moreover, IgD enhanced the effect of LPS on production of 
both IL-1 P and TNF-a, although the effect was most apparent 
for TNF-a. These findings suggest a role of IgD in the 
pathogenesis of HIDS. IgD, being present in increased 
concentrations in these patients, could participate in the 
activation of the cytokine network during febrile attacks in 
these patients by the virtue of its cytokine-inducing capacity.6
The cytokine-releasing effect of IgD is impressive and 
similar to that of LPS, which is regarded as one of the most 
potent biological stimuli for cytokine release from PBMC. It is 
unlikely that the effect of IgD is mediated via complement 
activation, as addition of complement-containing serum did 
not influence the cytokine release. Preliminary results also 
indicate that IgD is able to induce IL-6, IL-10, soluble TN F 
receptor p75, and leukaemia inhibitory factor release from 
PBMC (J. P. H. Drenth, unpublished observations). It is 
unlikely that the observed effects of IgD are a result of LPS 
contamination. First, we detected an endotoxin concentration 
of less than 6 pg/ml in our IgD stock solution (150 mg/1). In our 
experiments, IgD in a concentration of 0-05 mg/1 already 
induced cytokine secretion, and because this represents a 
dilution of 1:3000 of the stock solution this sample cannot 
contain over 0-002pg/ml LPS. It has been shown that the LPS 
concentration must exceed 10 pg/ml in order to observe a 
significant induction of cytokine secretion from human 
PBMC,23 In addition, incubation with polymyxin B did not 
affect its cytokine-eliciting effects in PBMC.
Lastly, exposure of the IgD preparation for 1 hr to a 
temperature of 100° resulted in complete disappearance of the 
cytokine-eliciting effect. Endotoxin degrades only after 4 hr 
exposure to.1800,24
Human IgD is a protein of MW 185 000 with a heavy chain 
consisting of four domains, an Fc region that is highly resistant 
to proteolysis, and a more labile Fab, It has been postulated 
that it may serve as a signalling mechanism to the T-cell 
population and, experimentally, it augments the antibody 
response to a variety of antigens. Peripheral blood CD4+ and 
CD8 * lymphocytes from healthy donors express receptors for 
IgD and are denoted as T5 cells.25 In contrast to other 
immunoglobulin receptors, such as those for IgG, IgA> IgE and 
IgM, the IgD receptor is not specific only for the Fc region o f 
IgD, There is strong evidence that murine IgD receptors are 
lectins, which bind not only to the Fc<!> receptors but also to 
N-linked IgD-associated, carbohydrates.27 Exposure to oligo­
meric IgD and IL-2, IL-4 and IFN-y results in up-regulation o f 
these receptors.28 IgD may thus play a role in the regulation of 
immune responses via its recognition of these IgD-receptor- 
positive cells. Most probably, effective binding of IgD to these 
cells is needed to induce the cytokine-producing machinery 
and to explain the impressive and rapid cytokine release. Our 
data indicate that monocytes are the main producers of 
cytokines in the presence of IgD. Co-operation of lymphocytes 
and monocytes does not seem to play a role. It would be 
interesting to know whether IgD affects the transcription of 
mRNA for the various cytokines or that post-transcriptional 
mechanisms play a role. Further studies are underway to 
elucidate this issue. From our studies we cannot conclude
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whether the cytokine-inducing effect is specific for IgD isolated 
from hyper-IgD patients, or that it also applies to IgD isolated 
from other sources such as patients with IgD myeloma. The 
structure of IgD from both diseases however differs, and more 
than 90% of the IgD myelomas consist of lambda light chains, 
while the kappa/lambda light chain ratio is elevated in the 
hyper-IgD syndrome. Whether this structural difference 
results in a distinct cytokine-inducing effect will be addressed in 
a future study.
The cytokine-releasing effect of another immunoglobulin, 
IgG, has been investigated to some extent. Our finding of 
increased IL-lra production with virtually absent production 
of pro-inflammatory cytokines in PBMC cultures incubated 
with IgG is in accordance with other studies.31 Culture of 
monocytes on adherent IgG specifically increases IL-lra 
production but cells fail to release IL-1/?.32 In our study, 
incubation with IgG failed to elicit either IL-1/? or TNF-a 
secretion but enhanced IL-lra release.
During the febrile attacks of the HIDS, a variety of acute 
phase proteins (serum amyloid A, and CRP) are produced and 
can be found in appreciable concentrations in the circulation. 
Moreover, during, but also between attacks, there are high 
circulating concentrations of AGP and the fucosylation of this 
protein dramatically changes during the febrile episodes.7 
Incubation of AGP, in our study, resulted in a dose-dependent 
increase of release of IL-1/?, TNF-a and also IL-lra; the effect 
was most evident at a concentration of 750 ¿fg/ml. Human AGP 
significantly enhanced the LPS-induced secretion of IL-l/i but 
did not affect TNF-a and IL-lra release. AGP has been shown 
to induce the synthesis of IL-1/? and IL-lra in human PBMC.33 
In other studies AGP acted synergistically with low concen­
trations with LPS in the induction of IL-1/?, TNF-a, IL-6 and 
IL-lra.33,34 However; compared with IgD, the cytokine- 
enhancing effect of AGP is only moderate. During the acute 
phase response AGP undergoes extensive post-translational 
modification, with the acquisition of sialyl-Lewis-X containing 
glycans and shift of glycosylation with increase of biantennary 
glycans.7 We used AGP obtained from the Cohn fraction V of 
pooled human serum. It is possible that the induction of these 
cytokines depends on the extent of glycosylation of AGP, but 
this requires further investigation. Another acute phase 
protein, CRP, seems to be a more potent producer of IL-la, 
IL-1/?, IL-6, TNF-a and IL-lra and also potentiates the LPS- 
induced secretion of these inflammatory mediators.11,33 All in 
all, these findings imply that the acute-phase proteins may serve 
an immunomodulatory role in attacks of the hyper-IgD 
syndrome by augmenting the cytokine release from PBMC.
From our results it is apparent that IgD stimulates human 
PBMC to secrete pro inflammatory cytokines such as IL-1/? but 
also of an inhibitor like IL-lra. The amounts of IL-1 /? by far 
exceed those of IL-lra. Excess concentrations of IL-lra (100- to 
1000-fold excess) must be present in order to yield a significant 
inhibition of IL-1-induced responses and thus the amount may 
be inadequate in the acute inflammation.
Although IgD is a potent stimulator of cytokines, its precise 
role in the pathogenesis of the syndrome remains to be clarified 
further. For example, a clear correlation between the serum 
concentration of IgD and the frequency or severity of the 
attacks is absent.5 However, it is possible that attacks in the 
hyper-IgD syndrome are precipitated by the inactivation of an 
(as yet unidentified) inhibitory compound that allows IgD to
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elicit an exaggerated cytokine response. In this respect IgD may 
function in a dual role, amplifying the inflammatory response 
by release of proinflammatory cytokines but also serving a 
down-regulating role by eliciting the production of IL-lra. In 
this way IgD can act as a factor in maintaining the inflam­
matory response during the febrile attacks of the hyper-IgD 
syndrome.
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